Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Up 0.8% – Time to Buy?

Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) were up 0.8% during trading on Tuesday . The stock traded as high as $12.13 and last traded at $12.05. Approximately 5,118 shares were traded during trading, a decline of 82% from the average daily volume of 28,449 shares. The stock had previously closed at $11.95.

Finch Therapeutics Group Stock Performance

The business’s fifty day moving average price is $11.91 and its two-hundred day moving average price is $6.20. The stock has a market capitalization of $18.47 million, a P/E ratio of -1.36 and a beta of 1.34.

Finch Therapeutics Group (NASDAQ:FNCH) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($3.01) earnings per share for the quarter.

Institutional Investors Weigh In On Finch Therapeutics Group

A hedge fund recently bought a new stake in Finch Therapeutics Group stock. Lake Street Advisors Group LLC bought a new stake in shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 21,206 shares of the company’s stock, valued at approximately $56,000. Lake Street Advisors Group LLC owned 1.32% of Finch Therapeutics Group at the end of the most recent quarter. 21.77% of the stock is currently owned by institutional investors.

Finch Therapeutics Group Company Profile

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.